The Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai 980 KOBAYASHI, K., MIURA, Y., TOMIOKA, H., SAKUMA, H., ADACHI, M., ABE, K. and YOSHINAGA, K. Interference with Fluorimetric Assay of Catecholamine by Labetalol. Tohoku J. exp. Med., 1978, 126 (2), 201-202 - Influence of labetalol and 5-(1-hydroxy-2-aminoethyl)salieylamide (SA), a part of the chemical structure of labetalol, on the fluorimetric assay of catecholamine (CA) was studied. Both labetalol and SA have a weak but significant fluorescence which is indistinguishable from that of CA with peaks of excitation/emission wavelengths at 410/490. It is thus concluded that an apparent increase in urinary CA observed in patients receiving labetalol is caused by the contamination of labetalol and/or its metab olite, and that the evaluation of urinary CA in hypertensive patients must be done prior to the use of labetalol to avoid any confusion in diagnosis of pheo chromocytoma.
catecholamine; flurimetry; labetalol The fluorescence intensities of these agents after processing through the whole THI procedures (Miura et al. 1977 ) were compared with those of norepinephrine (NE) and epinephrine (E), using a fluorescence spectrophotometer (Hitachi, MPF type IV) at two sets of wavelengths of excitation/emission (410/490 and 452/490 nm, uncorrected). Table 1 shows the relative fluorescence intensity of each agent.
Not only labetalol but also SA showed weak but significant fluorescence which is indistinguishable from those of CA with peaks of excitation/emission wavelengths at 410/490. The fluorescence intensity of 50 mg of labetalol was equivalent to 0.3 ng of NE plus 0.7 g of E (1.0 ng of total CA), while 5 µg of SA was equal to 1.9 ng of NE plus 1.2 ng of E (3.1 ng of total CA). The fluorescence intensity of SA was about 30 times stronger than that of labetalol itself.
From these data, it is evident that labetalol and SA elicit CA-like fluorescence through THI oxidation and interfere significantly with CA assay. It seems likely that an augmenta tion of urinary CA excretion under labetalol treatment is partly due to labetalol itself, and partly due to a more strongly fluorescent metabolite such as 5-(1-hydroxy-2-aminoethyl)-salicylamide which may be produced by a cleavage of labetalol molecule in vivo. These non-catecholamine fluorescence may account for falsely high output of urinary CA in the patients. An evaluation of urinary CA in hypertensive patients must be performed prior to the use of labetalol in order that an erroneous diagnosis of pheochromocytoma may not be made. 
